RAPT Therapeutics, Inc. (RAPT)
NASDAQ$1.14
Market Cap
$150.49M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
798 of 924
Rank in Industry
450 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
RAPT Insider Trading Activity
RAPT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 …
Insider Activity of RAPT Therapeutics, Inc.
Over the last 12 months, insiders at RAPT Therapeutics, Inc. have bought $0 and sold $0 worth of RAPT Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at RAPT Therapeutics, Inc. have bought $4.93M and sold $36.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $97,612 was made by Robbins Wendye (director) on 2023‑03‑14.
List of Insider Buy and Sell Transactions, RAPT Therapeutics, Inc.
| 2024-01-05 | Sale | Brockstedt Dirk G. | CHIEF SCIENTIFIC OFFICER | 898 0.0025% | $22.78 | $20,456 | -86.46% | |
| 2023-12-21 | Sale | HO WILLIAM | Chief Medical Officer | 2,500 0.007% | $21.68 | $54,200 | -84.99% | |
| 2023-11-28 | Sale | HO WILLIAM | Chief Medical Officer | 1,500 0.0042% | $13.72 | $20,580 | -71.91% | |
| 2023-10-03 | Sale | HO WILLIAM | Chief Medical Officer | 2,500 0.0072% | $15.77 | $39,425 | -44.90% | |
| 2023-08-18 | Sale | HO WILLIAM | Chief Medical Officer | 2,500 0.0072% | $18.92 | $47,300 | -43.67% | |
| 2023-04-19 | Sale | HO WILLIAM | Chief Medical Officer | 5,000 0.015% | $18.88 | $94,400 | -1.09% | |
| 2023-03-14 | Robbins Wendye | director | 5,000 0.0152% | $19.52 | $97,612 | -2.84% | ||
| 2023-03-07 | Sale | HO WILLIAM | 5,000 0.015% | $29.62 | $148,100 | -36.46% | ||
| 2023-01-24 | Sale | HO WILLIAM | Chief Medical Officer | 5,000 0.0162% | $30.00 | $150,000 | -31.27% | |
| 2023-01-19 | Sale | HO WILLIAM | Chief Medical Officer | 5,000 0.0146% | $25.56 | $127,800 | -27.26% | |
| 2023-01-05 | Sale | Brockstedt Dirk G. | Chief Scientific Officer | 742 0.0022% | $21.97 | $16,299 | -13.46% | |
| 2022-12-29 | Sale | HO WILLIAM | Chief Medical Officer | 5,000 0.0132% | $18.03 | $90,150 | +2.46% | |
| 2022-11-28 | Sale | HO WILLIAM | Chief Medical Officer | 5,000 0.0144% | $17.87 | $89,350 | +10.82% | |
| 2022-11-02 | Sale | HO WILLIAM | Chief Medical Officer | 5,000 0.0144% | $22.32 | $111,600 | -10.39% | |
| 2022-10-13 | Sale | HO WILLIAM | Chief Medical Officer | 2,000 0.0054% | $21.52 | $43,040 | -10.07% | |
| 2022-08-30 | Sale | HO WILLIAM | Chief Medical Officer | 2,500 0.0079% | $28.13 | $70,325 | -20.37% | |
| 2022-07-11 | Sale | HO WILLIAM | Chief Medical Officer | 2,000 0.006% | $19.95 | $39,900 | +6.92% | |
| 2022-05-25 | Column Group LLC | 1,837 0.0054% | $12.45 | $22,880 | +54.33% | |||
| 2022-05-25 | TCG IV GP, LLC | 63 0.0002% | $12.45 | $785 | +54.33% | |||
| 2022-05-23 | Column Group LLC | 15,776 0.0484% | $12.00 | $189,345 | +67.60% |
Total: 126
Insider Historical Profitability
37.32%
| GOEDDEL DAVID V | director | 4982333 3.7743% | $5.68M | 1 | 0 | +107.48% |
| Topspin Fund L.P. | director | 2575371 1.9509% | $2.94M | 1 | 0 | +107.48% |
| Column Group LLC | 1236261 0.9365% | $1.41M | 3 | 0 | +69.16% | |
| Wong Brian Russell | President and CEO | 337000 0.2553% | $384,180.00 | 2 | 1 | +43.65% |
| TCG IV GP, LLC | 42189 0.032% | $48,095.46 | 3 | 0 | +69.16% |
Historical Insider Profitability vs. Competitors
$30,470,407 | 140 | 20.39% | $134.78M | |
$860,541,348 | 82 | -5.10% | $132.49M | |
$2,924,567 | 72 | -4.87% | $157.74M | |
$64,487,106 | 32 | -22.92% | $140.02M | |
RAPT Therapeutics, Inc. (RAPT) | $35,190,048 | 32 | 37.32% | $150.49M |
RAPT Institutional Investors: Active Positions
| Increased Positions | 60 | +51.72% | 105M | +355.21% |
| Decreased Positions | 52 | -44.83% | 7M | -24.89% |
| New Positions | 28 | New | 97M | New |
| Sold Out Positions | 33 | Sold Out | 3M | Sold Out |
| Total Postitions | 124 | +6.9% | 127M | +330.32% |
RAPT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Medicxi Ventures Management (Jersey) Ltd | $25,481.00 | 16.93% | 22.35M | +22M | New | 2024-12-31 |
| Orbimed Advisors Llc | $14,974.00 | 9.95% | 13.14M | +13M | New | 2024-12-31 |
| Tcg Crossover Management, Llc | $14,974.00 | 9.95% | 13.14M | +13M | New | 2024-12-31 |
| Foresite Capital Management Vi Llc | $14,250.00 | 9.47% | 12.5M | +13M | New | 2024-12-31 |
| Rtw Investments, Lp | $13,411.00 | 8.91% | 11.76M | +12M | New | 2024-12-31 |
| Bvf Inc/Il | $10,531.00 | 7% | 9.24M | +9M | New | 2024-12-31 |
| Redmile Group, Llc | $7,382.00 | 4.91% | 6.48M | +6M | +1,183.43% | 2024-12-31 |
| Deep Track Capital, Lp | $6,853.00 | 4.55% | 6.01M | +6M | New | 2024-12-31 |
| Perceptive Advisors Llc | $6,703.00 | 4.46% | 5.88M | +6M | New | 2024-12-31 |
| Fmr Llc | $5,966.00 | 3.96% | 5.23M | -2,470 | -0.05% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.